Shots:
- KYORIN and Novartis entered into a global license agreement for KRP-M223 and its back-up compounds discovered by KYORIN
- As per the agreement, Novartis gets an exclusive global license to develop, manufacture, and commercialize KRP-M223, where KYORIN retains an option to commercialize and manufacture product for the Japanese market, with Novartis retaining an option to co-promote with KYORIN in Japan. Additionally, KRP-M223 is in pre-clinical stage, and Novartis will handle its global development
- KYORIN will receive $55M upfront payment and up to $777.5M milestone payments based on the progress of development, approval, and commercialization of KRPM223, along with tiered royalties on net sales
Ref: KYORIN | Image: KYORIN & Novartis
Related News:- Novartis to Acquire Anthos Therapeutics for ~$3.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
